Incoming Storm
Release form and composition
Lizinopril is produced in the form of tablets: round, with beveled edges, pink, orange, dark orange, white or almost white, flat, with a risk on one side (in blister packs of 10 pcs., 2, 3, 4 , 5 or 6 packs in a cardboard bundle; in packaged blister packs of 14 pcs., 1, 2, 3 or 4 packs in a cardboard bundle).
Composition of 1 tablet:
- Active ingredient: lisinopril (in the form of a dihydrate) - 2.5 mg (dark orange tablets), 5 mg (orange tablets), 10 mg (pink tablets), 20 mg (white tablets);
- Auxiliary components: corn starch, magnesium stearate, methylene chloride, lactose monohydrate, talc, povidone, dye azorubine (pink tablets), sunset yellow dye (orange and dark orange tablets), titanium dioxide (white tablets).
Contraindications Lisinopril
- increased susceptibility to the active substance or other ACE inhibitors or one of the excipients;
- renal artery stenosis (bilateral or unilateral with one kidney);
- history of angioedema due to previous ACE therapy and hereditary / spontaneous angioedema;
- concomitant use of lisinopril with products containing aliskiren in patients with diabetes mellitus or renal failure (GFR
Pharmacodynamics
inhibitor of angiotensin-converting enzyme (ACE inhibitor).
ACE suppression leads to a reduced formation of angiotensin II (with a vasoconstrictor effect) and to a decrease in aldosterone secretion.
Lisinopril-Teva also blocks the breakdown of bradykinin, a potent vasodepressor peptide.
As a result, it reduces blood pressure, total peripheral vascular resistance, pre- and afterload on the heart, increases minute volume, cardiac output and increases myocardial tolerance to loads and improves blood supply to the ischemic myocardium.
In patients with acute myocardial infarction, Lisinopril-Teva, together with nitrates, reduces the formation of left ventricular dysfunction or heart failure.